British Society for Echocardiography and British Cardio-Oncology Society guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab
Dobson, Rebecca Ghosh, Arjun K Ky, Bonnie Marwick, Tom Stout, Martin Harkness, Allan Steeds, Rick Robinson, Shaun Oxborough, David Adlam, David
Dobson, Rebecca
Ghosh, Arjun K
Ky, Bonnie
Marwick, Tom
Stout, Martin
Harkness, Allan
Steeds, Rick
Robinson, Shaun
Oxborough, David
Adlam, David
Citations
Altmetric:
Affiliation
Liverpool Heart and Chest NHS Foundation Trust; Barts Health NHS Trust; University College London; University College London Hospitals NHS Foundation Trust; University of Pennsylvania; Baker Heart and Diabetes Institute, Melbourne; University Hospital South Manchester NHS Foundation Trust; East Suffolk and North Essex NHS Foundation Trust; University Hospitals Birmingham NHS Foundation Trust; North West Anglia NHS Foundation Trust; Liverpool John Moores University; University Hospitals of Leicester NHS Trust; Imperial College Healthcare NHS Trust; The Shrewsbury and Telford Hospital NHS Trust; West Suffolk NHS Foundation Trust; Royal Brompton and Harefield NHS Foundation Trust; Imperial College London; The Newcastle upon Tyne Hospitals NHS Foundation Trust; Belfast Health and Social Care Trust; Royal Liverpool and Broadgreen University Hospitals NHS Trust; Royal United Hospitals Bath NHS Foundation Trust; University of Bath
Other Contributors
Publication date
2021-03-03
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
The subspecialty of cardio-oncology aims to reduce cardiovascular morbidity and mortality in patients with cancer or following cancer treatment. Cancer therapy can lead to a variety of cardiovascular complications, including left ventricular systolic dysfunction, pericardial disease, and valvular heart disease. Echocardiography is a key diagnostic imaging tool in the diagnosis and surveillance for many of these complications. The baseline assessment and subsequent surveillance of patients undergoing treatment with anthracyclines and/or human epidermal growth factor (EGF) receptor (HER) 2-positive targeted treatment (e.g. trastuzumab and pertuzumab) form a significant proportion of cardio-oncology patients undergoing echocardiography. This guideline from the British Society of Echocardiography and British Cardio-Oncology Society outlines a protocol for baseline and surveillance echocardiography of patients undergoing treatment with anthracyclines and/or trastuzumab. The methodology for acquisition of images and the advantages and disadvantages of techniques are discussed. Echocardiographic definitions for considering cancer therapeutics-related cardiac dysfunction are also presented.
Citation
Dobson R, Ghosh AK, Ky B, Marwick T, Stout M, Harkness A, Steeds R, Robinson S, Oxborough D, Adlam D, Stanway S, Rana B, Ingram T, Ring L, Rosen S, Plummer C, Manisty C, Harbinson M, Sharma V, Pearce K, Lyon AR, Augustine DX. British Society for Echocardiography and British Cardio-Oncology Society guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab. Echo Res Pract. 2021 Mar 31;8(1):G1-G18. doi: 10.1530/ERP-21-0001.
Type
Article